Domínguez José M, Nilo Flavia, Martínez María T, Massardo José M, Muñoz Sueli, Contreras Tania, Carmona Rocío, Jerez Joaquín, González Hernán, Droppelmann Nicolás, León Augusto
Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Department of Surgery, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Arch Endocrinol Metab. 2018 Feb;62(1):6-13. doi: 10.20945/2359-3997000000013.
Objective We aimed to describe the presentation of papillary microcarcinoma (PTMC) and identify the clinical and histological features associated with persistence/recurrence in a Latin American cohort. Subjects and methods Retrospective study of PTMC patients who underwent total thyroidectomy, with or without radioactive iodine (RAI), and who were followed for at least 2 years. Risk of recurrence was estimated with ATA 2009 and 2015 classifications, and risk of mortality with 7th and 8th AJCC/TNM systems. Clinical data obtained during follow-up were used to detect structural and biochemical persistence/recurrence. Results We included 209 patients, predominantly female (90%), 44.5 ± 12.6 years old, 183 (88%) received RAI (90.4 ± 44.2 mCi), followed-up for a median of 4.4 years (range 2.0-7.8). The 7th and 8th AJCC/TNM system classified 89% and 95.2% of the patients as stage I, respectively. ATA 2009 and ATA 2015 classified 70.8% and 78.5% of the patients as low risk, respectively. Fifteen (7%) patients had persistence/recurrence during follow-up. In multivariate analysis, only lymph node metastasis was associated with persistence/recurrence (coefficient beta 4.0, p = 0.016; 95% CI 1.3-12.9). There were no PTMC related deaths. Conclusions Our series found no mortality and low rate of persistence/recurrence associated with PTMC. Lymph node metastasis was the only feature associated with recurrence in multivariate analysis. The updated ATA 2015 and 8th AJCC/TNM systems classified more PTMCs than previous classifications as low risk of recurrence and mortality, respectively.
目的 我们旨在描述微小乳头状癌(PTMC)的表现,并确定拉丁美洲队列中与持续存在/复发相关的临床和组织学特征。对象与方法 对接受全甲状腺切除术(无论是否接受放射性碘治疗)且随访至少2年的PTMC患者进行回顾性研究。采用美国甲状腺协会(ATA)2009年和2015年分类评估复发风险,采用美国癌症联合委员会(AJCC)/国际抗癌联盟(TNM)第7版和第8版系统评估死亡风险。随访期间获得的临床数据用于检测结构和生化方面的持续存在/复发情况。结果 我们纳入了209例患者,以女性为主(90%),年龄44.5±12.6岁,183例(88%)接受了放射性碘治疗(90.4±44.2毫居里),中位随访时间为4.4年(范围2.0 - 7.8年)。AJCC/TNM第7版和第8版系统分别将89%和95.2%的患者分类为I期。ATA 2009年和ATA 2015年分别将70.8%和78.5%的患者分类为低风险。15例(7%)患者在随访期间出现持续存在/复发。多因素分析显示,仅淋巴结转移与持续存在/复发相关(系数β为4.0,p = 0.016;95%置信区间1.3 - 12.9)。未发生与PTMC相关的死亡。结论 我们的系列研究发现PTMC相关死亡率低且持续存在/复发率低。多因素分析中,淋巴结转移是与复发相关的唯一特征。更新后的ATA 2015年和AJCC/TNM第8版系统分别将更多的PTMC分类为复发和死亡低风险,较之前的分类有所增加。